Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 46 articles:
HTML format
Text format



Single Articles


    June 2018
  1. SHINDE A, Jones BL, Chen YJ, Amini A, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma: Does Radiation Dose Make a Difference?
    J Clin Oncol. 2018 Jun 26:JCO2018786012. doi: 10.1200/JCO.2018.78.6012.
    PubMed     Text format    


  2. FIORENTINO A, Alongi F
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial?
    J Clin Oncol. 2018 Jun 26:JCO2018781005. doi: 10.1200/JCO.2018.78.1005.
    PubMed     Text format    


  3. OHRI N, Kabarriti R, Kaubisch A, Guha C, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: Caution When Interpreting Observational Data.
    J Clin Oncol. 2018 Jun 26:JCO2018780122. doi: 10.1200/JCO.2018.78.0122.
    PubMed     Text format    


  4. WAHL DR, Schipper MJ, Parikh ND, Owen D, et al
    Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma?
    J Clin Oncol. 2018 Jun 26:JCO2018780882. doi: 10.1200/JCO.2018.78.0882.
    PubMed     Text format    


  5. KIM N, Seong J
    What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma?
    J Clin Oncol. 2018 Jun 26:JCO2018781740. doi: 10.1200/JCO.2018.78.1740.
    PubMed     Text format    


  6. SANUKI N, Takeda A
    Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma?
    J Clin Oncol. 2018 Jun 26:JCO2018782805. doi: 10.1200/JCO.2018.78.2805.
    PubMed     Text format    


  7. OLSEN JR, Murphy JD, Hallemeier CL, Apisarnthanarax S, et al
    Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database.
    J Clin Oncol. 2018 Jun 26:JCO2018782904. doi: 10.1200/JCO.2018.78.2904.
    PubMed     Text format    


  8. SMITH GL, Das P, Herman JM, Koay EJ, et al
    Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data.
    J Clin Oncol. 2018 Jun 26:JCO2018785428. doi: 10.1200/JCO.2018.78.5428.
    PubMed     Text format    


    May 2018
  9. RIAZ A, Lewandowski R, Salem R
    Radioembolization in Advanced Hepatocellular Carcinoma.
    J Clin Oncol. 2018 May 2:JCO2018777227. doi: 10.1200/JCO.2018.77.7227.
    PubMed     Text format     Abstract available


    March 2018
  10. CHOW PKH, Gandhi M, Tan SB, Khin MW, et al
    SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
    J Clin Oncol. 2018 Mar 2:JCO2017760892. doi: 10.1200/JCO.2017.76.0892.
    PubMed     Text format     Abstract available


    January 2018
  11. RAJYAGURU DJ, Borgert AJ, Smith AL, Thomes RM, et al
    Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
    J Clin Oncol. 2018 Jan 12:JCO2017753228. doi: 10.1200/JCO.2017.75.3228.
    PubMed     Text format     Abstract available


    September 2017
  12. O'NEILL AF, Towbin AJ, Krailo MD, Xia C, et al
    Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 Sep 11:JCO2017735654. doi: 10.1200/JCO.2017.73.5654.
    PubMed     Text format     Abstract available


  13. REISS KA, Yu S, Mamtani R, Mehta R, et al
    Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
    J Clin Oncol. 2017 Sep 5:JCO2017738245. doi: 10.1200/JCO.2017.73.8245.
    PubMed     Text format     Abstract available


    August 2017
  14. IKOMA N, You YN, Bednarski BK, Rodriguez-Bigas MA, et al
    Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.
    J Clin Oncol. 2017;35:2631-2638.
    PubMed     Text format     Abstract available


    May 2017
  15. PERSONENI N, Rimassa L, Giordano L, Santoro A, et al
    Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!
    J Clin Oncol. 2017 May 4:JCO2017727776. doi: 10.1200/JCO.2017.72.7776.
    PubMed     Text format    


    April 2017
  16. GROOT KOERKAMP B, Sadot E, Kemeny NE, Gonen M, et al
    Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.
    J Clin Oncol. 2017 Apr 20:JCO2016718346. doi: 10.1200/JCO.2016.71.8346.
    PubMed     Text format     Abstract available


  17. BRAILLON A
    Recurrence in Early-Stage Hepatocellular Carcinoma: CpG Methylation and Smoking.
    J Clin Oncol. 2017 Apr 11:JCO2017723932. doi: 10.1200/JCO.2017.72.3932.
    PubMed     Text format    


  18. PAGLIARO LC
    Role of High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Men With Previously Treated Germ Cell Tumors.
    J Clin Oncol. 2017;35:1036-1040.
    PubMed     Text format     Abstract available


    January 2017
  19. FERRAROTTO R, Mitani Y, Diao L, Guijarro I, et al
    Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    J Clin Oncol. 2017;35:352-360.
    PubMed     Text format     Abstract available


  20. ZHONG JH, Tan JT, Li LQ, Wu WS, et al
    Transarterial Embolization With or Without Chemotherapy: What Should Be the Indication for Patients With Hepatocellular Carcinoma?
    J Clin Oncol. 2017;35:257-258.
    PubMed     Text format    


  21. BOULIN M, Guiu B
    Chemoembolization or Bland Embolization for Hepatocellular Carcinoma: The Question Is Still Unanswered.
    J Clin Oncol. 2017;35:256-257.
    PubMed     Text format    


  22. BRAILLON A
    Delusional Beliefs and Hepatocellular Carcinoma.
    J Clin Oncol. 2017;35:256.
    PubMed     Text format    


  23. QIU J, Peng B, Tang Y, Qian Y, et al
    CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study.
    J Clin Oncol. 2017 Jan 9:JCO2016682153.
    PubMed     Text format     Abstract available


  24. JACKSON R, Psarelli EE, Berhane S, Khan H, et al
    Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
    J Clin Oncol. 2017 Jan 3:JCO2016695197.
    PubMed     Text format     Abstract available


  25. DONG R, Zheng S, Dong K
    Distinguishing Among Pediatric Hepatoblastomas, Transitional Liver Cell Tumors, and Hepatocellular Carcinomas and Using Appropriate Chemotherapy Regimens.
    J Clin Oncol. 2017;35:115-116.
    PubMed     Text format    


    December 2016
  26. NAGTEGAAL ID, Knijn N, Hugen N, Marshall HC, et al
    Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Dec 28:JCO2016689091.
    PubMed     Text format     Abstract available


  27. CLOUGHESY T, Finocchiaro G, Belda-Iniesta C, Recht L, et al
    Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA M
    J Clin Oncol. 2016 Dec 5:JCO2015647685.
    PubMed     Text format     Abstract available


    June 2016
  28. DE BARI B, Ozsahin M, Bize P, Boussaha T, et al
    Can Stereotactic Body Radiotherapy Really Be Considered the Preferred Treatment in Large Hepatocellular Carcinoma?
    J Clin Oncol. 2016 Jun 20. pii: JCO667196.
    PubMed     Text format    


  29. YANG JF, Lo CH, Huang WY
    Is Stereotactic Body Radiotherapy Better Than Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma?
    J Clin Oncol. 2016 Jun 20. pii: JCO664458.
    PubMed     Text format    


    April 2016
  30. PETRICK JL, Kelly SP, Altekruse SF, McGlynn KA, et al
    Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.
    J Clin Oncol. 2016 Apr 4. pii: JCO647412.
    PubMed     Text format     Abstract available


    March 2016
  31. DAL PRA A, Berlin A, Kumareswaran R, Schattner AJ, et al
    Liver Failure After Abdominal Irradiation: Identifying the Right Suspects.
    J Clin Oncol. 2016;34:e80-3.
    PubMed     Text format    


  32. AKTHAR AS, Golden DW, Nanda R, Sharma MR, et al
    Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus.
    J Clin Oncol. 2016;34:e73-5.
    PubMed     Text format    


  33. HALABI S, Kelly WK, Ma H, Zhou H, et al
    Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Mar 7. pii: JCO657270.
    PubMed     Text format     Abstract available


    February 2016
  34. SADOWSKI SM, Neychev V, Millo C, Shih J, et al
    Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    J Clin Oncol. 2016;34:588-96.
    PubMed     Text format     Abstract available


  35. BROWN KT, Do RK, Gonen M, Covey AM, et al
    Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.
    J Clin Oncol. 2016 Feb 1. pii: JCO640821.
    PubMed     Text format     Abstract available


    January 2016
  36. MURAWSKI M, Weeda VB, Maibach R, Morland B, et al
    Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies.
    J Clin Oncol. 2016 Jan 25. pii: JCO602250.
    PubMed     Text format     Abstract available


  37. FORCE J, Saxena R, Schneider BP, Storniolo AM, et al
    Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
    J Clin Oncol. 2016;34:e9-12.
    PubMed     Text format    


  38. BARNEA D, Abou-Alfa GK, Bromberg J, D'Angelica MI, et al
    Hepatic adenoma among adult survivors of childhood cancer.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


    December 2015
  39. BARRY A, Knox JJ, Wei AC, Dawson LA, et al
    Can Stereotactic Body Radiotherapy Effectively Treat Hepatocellular Carcinoma?
    J Clin Oncol. 2015 Dec 23. pii: JCO648097.
    PubMed     Text format     Abstract available


  40. HONG TS, Wo JY, Yeap BY, Ben-Josef E, et al
    Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    J Clin Oncol. 2015 Dec 14. pii: JCO642710.
    PubMed     Text format     Abstract available


  41. HURWITZ HI, Uppal N, Wagner SA, Bendell JC, et al
    Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    J Clin Oncol. 2015;33:4039-47.
    PubMed     Text format     Abstract available


    November 2015
  42. WAHL DR, Stenmark MH, Tao Y, Pollom EL, et al
    Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
    J Clin Oncol. 2015 Nov 30. pii: JCO614925.
    PubMed     Text format     Abstract available


  43. GRAZIANO P, de Marinis F, Gori B, Gasbarra R, et al
    EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.
    J Clin Oncol. 2015;33:e115-8.
    PubMed     Text format    


    October 2015
  44. NEGRI FV, Porta C
    Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
    J Clin Oncol. 2015;33:3219-20.
    PubMed     Text format    


  45. YE SL
    Reply to F.V. Negri et al.
    J Clin Oncol. 2015;33:3220-1.
    PubMed     Text format    


    September 2014
  46. HARDING DJ, MacQuillan G, Howman R, de Boer B, et al
    Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
    J Clin Oncol. 2014 Sep 29. pii: JCO.2013.50.1320.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: